Fluid restriction management in the treatment of COVID-19: a single-center observational study

被引:1
|
作者
Matsumura, Yosuke [1 ]
Sugiyama, Takuya [2 ]
Kondo, Natsuki [1 ]
Miyahara, Masaya [1 ]
Hanaoka, Noriyuki [1 ]
Nagashima, Hideaki [1 ]
Kasahara, Yuki [1 ]
Fujiyoshi, Naohiko [1 ]
Inada, Azusa [2 ]
Inaba, Shin [2 ]
机构
[1] Chiba Emergency Med Ctr, Dept Intens Care, 3-32-1 Isobe, Mihama, Chiba 2610012, Japan
[2] Chiba Emergency Med Ctr, Dept Anesthesiol, Chiba, Chiba, Japan
关键词
CRITICALLY-ILL; RESUSCITATION;
D O I
10.1038/s41598-022-22389-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The relationship between fluid management and the severity of illness, duration of treatment, and outcome of coronavirus disease 2019 (COVID-19) is not fully understood. This study aimed to evaluate whether weight change during hospitalization was associated with COVID-19 severity, length of hospital stay, and route of admission. In this study, we assessed the effectiveness of fluid restriction management in patients with severe COVID-19. COVID-19 patients admitted to our hospital between July 2020 and October 2021 were analyzed. Patients were treated with standard drug therapy based on the Japanese guidelines and respiratory support according to the severity of the disease. Early enteral nutrition, defecation management, and anticoagulation therapy were also administered. Fluid restriction management was performed using furosemide and continuous renal replacement therapy as needed unless hemodynamic instability or hyperlactatemia was present. Patient background, route of admission (ambulance, A; transfer, T), weight at admission and discharge, the severity of illness (oxygen therapy, G1; mechanical ventilation, G2; extracorporeal membrane oxygenation, G3), in-hospital mortality, and length of hospital stay were analyzed. There were 116 subjects: G1 (n = 48), G2 (n = 43), and G3 (n = 25), with ages (median [IQR]) of 58 (47-70), 65 (53-71.5), 56 (51-62) years, 40 (83.3%), 31 (72.1%), and 19 (76.0%) males, respectively. Hospital stays were 4.5 (2-7), 10 (7-16), and 18 (15-26) days, and the in-hospital mortality rates were 0 (0%), 7 (16.3%), and 8 (32%), respectively. Body mass index on admission was 26 (23.1-30.2), 27.1 (22.7-31.1), and 31.5 (27.1-33.1) kg/m(2), and weight loss during admission was 1.1 (0-2.9), 4.6 (2.3-5.7), 9.2 (5.6-10.5) kg (P < 0.001, Jonckheere-Terpstra test. Weight loss in the severe group (G2 + G3) was 3.4 (0.5-5.8) kg [A, n = 12] and 5.6 (4.4-9) kg [T, n = 43] [P = 0.026, Mann-Whitney U test]. The lengths of hospital stay were 5 (2-7), 9 (7-15), and 18 (12-26) days [P < 0.001, Jonckheere-Terpstra test]. In our fluid restriction management, patients with severe COVID-19 had significant longer hospital length of stay, weight loss, especially those who were transferred to the hospital.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Fluid restriction management in the treatment of COVID-19: a single-center observational study
    Yosuke Matsumura
    Takuya Sugiyama
    Natsuki Kondo
    Masaya Miyahara
    Noriyuki Hanaoka
    Hideaki Nagashima
    Yuki Kasahara
    Naohiko Fujiyoshi
    Azusa Inada
    Shin Inaba
    Scientific Reports, 12
  • [2] COVID-19 mortality and its risk factors: A single-center observational study
    Gupta, Ajay
    Katoch, Neena
    Gulati, Rachna
    Kumar, Vikas
    Singh, Sharmendra
    Garg, Ketan
    JOURNAL OF ACUTE DISEASE, 2021, 10 (06) : 252 - 257
  • [3] A single-center observational study on smoking behavior and preventive measures for COVID-19
    da Rosa Decker, Sergio Renato
    Dambros, Eduardo
    Bertoldi, Eduardo Gehling
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2021, 47 (06)
  • [4] OBESITY AND COVID-19: A SINGLE-CENTER STUDY
    Mijangos-Mendez, Julio
    Vargas-Obieta, Alexandra
    Garcia-Salcido, Roxana
    Ibarra-estrada, Miguel
    Lopez-Pulgarin, Jose
    Chavez-Pena, Quetzalcoatl
    Alvarez-Hernandez, Esther
    Lopez-Aguirre, Paulina
    Cruz-Munoz, Beatriz
    Aguirre-Avalos, Guadalupe
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 95 - 95
  • [5] Invasive fungal disease in COVID-19 patients: a single-center prospective observational study
    Adzic-Vukicevic, Tatjana
    Mladenovic, Milos
    Jovanovic, Snezana
    Soldatovic, Ivan
    Radovanovic-Spurnic, Aleksandra
    FRONTIERS IN MEDICINE, 2023, 10
  • [6] Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: A single-center observational study
    Kaya, Huseyin
    Kizilbay, Gozde Oksuzler
    Ilgazli, Ahmet Hamdi
    Ozgur, Emrah Gokay
    EURASIAN JOURNAL OF PULMONOLOGY, 2024, 26 (01) : 41 - 50
  • [7] Tocilizumab in patients with severe COVID-19: A single-center observational analysis
    Knorr, John P.
    Colomy, Veronika
    Mauriello, Christine M.
    Ha, Seung
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2813 - 2820
  • [8] Anticoagulation in COVID-19: a single-center retrospective study
    Roomi, Sohaib Sanan
    Saddique, Maryum
    Ullah, Waqas
    Haq, Shujaul
    Ashfaq, Ammar
    Madara, John
    Boigon, Margot
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2021, 11 (01): : 17 - 22
  • [9] Ketamine as a Supplementary Analgosedative in COVID-19 Patients on Mechanical Ventilation: A Single-Center Observational Study
    Baltali, Sevim
    Haliloglu, Murat
    Soyturk, Ayse Nur
    Erden, Veysel
    Toptas, Mehmet
    ISTANBUL MEDICAL JOURNAL, 2024, 25 (02): : 165 - 169
  • [10] COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy
    Vigano, Chiara
    Massironi, Sara
    Pirola, Lorena
    Cristoferi, Laura
    Fichera, Maria
    Bravo, Marianna
    Mauri, Martina
    Redaelli, Alessandro Ettore
    Dinelli, Marco Emilio
    Invernizzi, Pietro
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (11) : E138 - E139